Back
Science

GLP-1 Drugs Linked to Modestly Higher Risk of Osteoporosis and Gout in Observational Studies

Generated on: Last updated: 3 sources
View source

GLP-1 Medications Linked to Modest Rise in Osteoporosis and Gout Risk, Studies Suggest

Recent research presented at medical conferences suggests an association between the use of GLP-1 medications (such as semaglutide and liraglutide) and a modestly elevated risk of developing osteoporosis and gout.

Experts caution that the studies demonstrate correlation, not causation, and that the observed risks may be related to rapid weight loss itself rather than a direct effect of the drugs.

Study Findings

Three analyses of separate patient data sets were presented, all pointing to an increased incidence of bone and joint conditions among GLP-1 users compared to non-users.

Osteoporosis Risk

  • One study of over 146,000 adults with obesity and Type 2 diabetes found that approximately 4% of GLP-1 users developed osteoporosis, compared to just over 3% of non-users—a relative risk increase of approximately 30%.
  • A second study, which matched 73,483 GLP-1 users to a control group, found a 0.9% higher absolute risk of developing osteoporosis among those taking the medications.

Gout Risk

  • In the larger study, rates of gout were 7.4% for GLP-1 users versus 6.6% for non-users, representing an approximate 12% increased risk.
  • The smaller matched study found a 0.8% higher absolute risk of gout.

Osteomalacia and Other Conditions

  • Osteomalacia, a rare condition involving bone softening, occurred about twice as often in GLP-1 users in one study, while another found a 0.1% higher absolute risk.
  • One analysis also noted a nearly doubling of the risk for bone mineral density issues over a five-year period.

Proposed Mechanisms

Researchers and clinicians have suggested several potential explanations for the observed associations, none of which have been definitively proven.

  • Mechanical Unloading: Rapid weight and muscle loss may reduce the mechanical load on bones, leading to decreased bone density.
  • Nutritional Deficiencies: Appetite suppression caused by GLP-1 drugs can result in reduced intake of protein, calcium, and vitamin D, all essential for bone health.
  • Metabolic Changes: Rapid weight loss can temporarily elevate uric acid levels, a known factor in gout. Some studies have also suggested GLP-1 drugs may disrupt calcium production.
  • Bone Remodeling: Changes in bone remodeling processes associated with fast weight reduction may contribute to bone loss.

Expert Commentary

Medical professionals not involved in the studies emphasized the limitations of the research.

"The studies are observational and cannot prove that the medications caused the conditions." — Dr. Clifford Rosen, Tufts University

Dr. Rosen also noted that the research lacked detailed data on patients' diets, exercise habits, or supplement use.

"Is the increased risk due to the rapid weight loss itself or another mechanism of the drug?" — Dr. Susan Spratt, Duke Health

Dr. Spratt also highlighted contradictory evidence, noting that some studies suggest musculoskeletal benefits and improvements in joint pain among GLP-1 users who lose weight. Separately, a study presented at the same conference indicated that GLP-1 users had better recovery outcomes from orthopedic procedures like hip and knee replacements.

"Combining GLP-1s with structured exercise could largely mitigate bone density loss." — Dr. Christopher McGowan, Gastroenterologist

Recommendations

Study authors and clinicians recommend that patients using GLP-1 medications be monitored for bone health, particularly those already at risk for osteoporosis, gout, or osteomalacia.

Angela Roy, a physician's assistant, emphasized the importance of strength training for maintaining bone health during GLP-1 use.

Experts generally agreed that the findings should not alter current prescribing practices but should reinforce the need for comprehensive obesity treatment that includes guidance on protein intake, exercise, and bone health monitoring.

Background

Osteoporosis is a disorder characterized by weakened bones that are prone to fractures.

Gout is a form of arthritis resulting from excess uric acid.

Previous research, including a February study published in the Journal of Clinical Endocrinology & Metabolism, has linked GLP-1 drugs to an increased risk of osteoporosis-related fractures in older adults with Type 2 diabetes.

The FDA label for semaglutide mentions a potential increase in bone fracture risk in older adults and women.